Evelin Schröck is a senior academic clinical geneticist, full professor of clinical genetics at the University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany. Her clinical and research work focusses on advancing genetic technologies and tumor genetics and is aimed at improving highly specialized healthcare for patients and families with hereditary cancer as well as intellectual disability. She also acts as Co-Director for the Core Unit for Molecular tumor Diagnostic (CMTD) and is a member of the board of directors at the National Center for Tumor Diseases (NCT) Dresden. She has also been appointed as president for the board of administration of the National Health Laboratory (LNS) of Luxembourg as well as Max Planck Fellow of the Max Planck Society and the Max Planck Institute of Molecular Cell Biology and Genetics, Dresden.
Hereditary monogenetic variants can lead to an increased cancer risk for all affected family members and have implications for cancer surveillance, treatment options and genetic testing. In this webinar, Evelin Schröck will summarize the results of a large-scale precision oncology study performed within the German DKTK MASTER program. In this observational trial prospective and comprehensive massive parallel tumor and control exome/genome sequencing is performed and is used for the recommendation of targeted treatment options. Germline variant evaluation is part of the workflow and a retrospective analysis of germline variant evaluation and its clinical impact for nearly 1,500 retrospectively analyzed patients will be presented. She will emphasize on the relevance of precision oncology studies to identify patients at risk for genetic tumor risk syndromes and their contribution to an improved multidisciplinary clinical decision making for these patients.